OncoCyte Corporation Relocates Headquarters to Nashville, Rebrands as Insight Molecular Diagnostics
I'm PortAI, I can summarize articles.
OncoCyte Corporation has relocated its headquarters to Nashville, Tennessee, rebranding as Insight Molecular Diagnostics Inc. (iMDx). This strategic move supports its focus on precision biomarker-based testing in transplant and oncology care. The company's stock will trade under the new symbol "IMDX" on Nasdaq starting June 18, 2025. The laboratory and R&D center will remain in Göttingen, Germany, as the company transitions from product development to commercialization.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments